HLS Therapeutics Inc.
HLTRFOTCHealthcare● Active
$3.15
+$0.00(+0.00%)
Market Cap$98512155
P/E Ratio—
52W High$4.02
52W Low$3
HLS Therapeutics Inc. (HLTRF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HLTRF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.07
Est. -$0.12 · +41.7%
Revenue
$0.01B
Est. $0.01B · -0.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
HLTRF reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.11
Rev. $0.17B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.11
Rev. Est.$0.17B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.08 | — | — | — | $0.01B | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$0.12 | -$0.07 | +41.7% | $0.01B | $0.01B | -0.0% |
| ▼ Q1 FY2026 | Mar 12, 2026 | -$0.03 | -$0.04 | -33.3% | $0.02B | $0.02B | +0.9% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -$0.06 | -$0.12 | -100.3% | $0.01B | $0.02B | -10.3% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -$0.07 | -$0.09 | -15.9% | $0.01B | $0.01B | -2.0% |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.12 | -$0.14 | -16.5% | $0.01B | $0.01B | +0.8% |
| ▼ Q1 FY2025 | Mar 13, 2025 | -$0.09 | -$0.10 | -7.6% | $0.02B | $0.01B | +16.0% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.12 | -$0.15 | -22.0% | $0.01B | $0.02B | -10.3% |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.08
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.07
EPS Est.
-$0.12
EPS Surpr.
+41.7%
Revenue
$0.01B
Q1 FY2026
Mar 12, 2026Miss
EPS Actual
-$0.04
EPS Est.
-$0.03
EPS Surpr.
-33.3%
Revenue
$0.02B
Q4 FY2025
Nov 13, 2025Miss
EPS Actual
-$0.12
EPS Est.
-$0.06
EPS Surpr.
-100.3%
Revenue
$0.01B
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
-$0.09
EPS Est.
-$0.07
EPS Surpr.
-15.9%
Revenue
$0.01B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.14
EPS Est.
-$0.12
EPS Surpr.
-16.5%
Revenue
$0.01B
Q1 FY2025
Mar 13, 2025Miss
EPS Actual
-$0.10
EPS Est.
-$0.09
EPS Surpr.
-7.6%
Revenue
$0.02B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.15
EPS Est.
-$0.12
EPS Surpr.
-22.0%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.02 | $0.02 | $0.02 | 1 |
| Q3 FY2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q2 FY2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q1 FY2027 | $-0.04 | $-0.03 | $-0.03 | 1 |
| Q4 FY2026 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q3 FY2026 | $-0.06 | $-0.06 | $-0.06 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +41.7% | $3.42 | $3.42 | +0.00% |
| ▼ Q1 FY2026 | Mar 12, 2026 | -33.3% | $3.36 | $3.36 | +0.00% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -100.3% | $3.70 | $3.54 | -4.32% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -15.9% | $3.70 | $3.74 | +1.08% |
| ▼ Q2 FY2025 | May 8, 2025 | -16.5% | $3.22 | $3.22 | +0.00% |
| ▼ Q1 FY2025 | Mar 13, 2025 | -7.6% | $2.73 | $2.73 | +0.00% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -22.0% | $2.50 | $2.54 | +1.60% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -17.3% | $2.22 | $2.22 | +0.00% |
Q2 FY2026+0.00%
Report Date
May 15, 2026
EPS Beat/Miss
+41.7%
Price Before
$3.42
Price After
$3.42
Q1 FY2026+0.00%
Report Date
Mar 12, 2026
EPS Beat/Miss
-33.3%
Price Before
$3.36
Price After
$3.36
Q4 FY2025-4.32%
Report Date
Nov 13, 2025
EPS Beat/Miss
-100.3%
Price Before
$3.70
Price After
$3.54
Q3 FY2025+1.08%
Report Date
Aug 14, 2025
EPS Beat/Miss
-15.9%
Price Before
$3.70
Price After
$3.74
Q2 FY2025+0.00%
Report Date
May 8, 2025
EPS Beat/Miss
-16.5%
Price Before
$3.22
Price After
$3.22
Q1 FY2025+0.00%
Report Date
Mar 13, 2025
EPS Beat/Miss
-7.6%
Price Before
$2.73
Price After
$2.73
Q4 FY2024+1.60%
Report Date
Nov 7, 2024
EPS Beat/Miss
-22.0%
Price Before
$2.50
Price After
$2.54
Q3 FY2024+0.00%
Report Date
Aug 8, 2024
EPS Beat/Miss
-17.3%
Price Before
$2.22
Price After
$2.22
Avg Beat Reaction+0.00%
Avg Miss Reaction-0.23%
Beat Rate1 / 8 quarters
Largest Move-4.32% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HLTRF ends December
HLS Therapeutics Inc. (HLTRF) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.07 — beating the analyst consensus of $-0.12 by +41.7%. The next HLTRF earnings date is expected around September 1, 2026.
Each quarter, investors track HLTRF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HLTRF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HLTRF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HLTRF earnings · 5 questionsHLS Therapeutics Inc.'s next earnings report is expected around September 1, 2026. HLTRF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HLTRF historically reports after market close (AMC).
HLTRF earnings datewhen is HLTRF earningsHLTRF next earnings datewhen does HLTRF report earningsHLTRF earnings calendar
▸ Source: FMP · HLS Therapeutics Inc. SEC filings · US GAAP · HLS Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026